The Food and Drug Administration has approved a new pill designed to manage persistently high cholesterol levels. This approval introduces a more convenient option for patients who face a high risk of cardiovascular disease and heart attacks.
Unlike traditional cholesterol-lowering injections, Merck’s Lipfendra offers a daily oral alternative. This can simplify the treatment regimen for individuals struggling with high cholesterol, potentially improving adherence to prescribed therapies and overall heart health.
Dengue Fever Surge in U.S.: Florida’s Record Outbreak and Rising Cases Nationwide 
Tick Crisis on Martha’s Vineyard: A Growing Health Threat 
Reflections on Dementia, Ant Warfare, and College Affordability 
Early Detection of Atherosclerosis and Heart Disease Prevention 
Church Attendance Linked to Increased Sexual Satisfaction for Married Couples 
Dining with Loved Ones May Benefit Blood Sugar Levels